Lin Sian-Han, Lee Jang-Ming, Wu I-Hui
Department of Surgery, National Taiwan University Hospital, Taipei 10002, Taiwan.
Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital, Taipei 10002, Taiwan.
Biomedicines. 2021 Dec 12;9(12):1889. doi: 10.3390/biomedicines9121889.
Aortoesophageal fistula (AEF) caused by esophageal cancer (EC) is a rare but life-threatening complication. However, the optimal management strategy remains undetermined. Previous cases have demonstrated that thoracic endovascular aortic repair (TEVAR) is effective for prophylactic management. In our study, we evaluated the management of AEF with elective TEVAR over salvage TEVAR. In our single-center retrospective cohort study, forty-seven patients with cT4M0 EC were included in this study, and we divided them into salvage (Group S) and elective (Group E) groups based on whether TEVAR was performed before the hemorrhagic AEF occurred. Our study outcomes included survival and complication rate after TEVAR. Group E showed better overall 90-day survival and aortic-event-free survival in 90-day and 180-day over Group S. More patients in Group E could receive subsequent chemoradiotherapy or esophagectomy. Significantly fewer AEF-related complications, including recurrent hemorrhagic events after TEVAR, hypoperfusion-related organ injury, and bloodstream infection, were noted in Group E. In patients with advanced EC-invading aorta, elective TEVAR offered an early overall and aortic-event-free survival benefit compared to salvage TEVAR. By reducing the AEF-related complications, elective TEVAR could provide more patients receiving subsequent curative-intent treatment.
食管癌(EC)导致的主动脉食管瘘(AEF)是一种罕见但危及生命的并发症。然而,最佳治疗策略仍未确定。既往病例表明,胸主动脉腔内修复术(TEVAR)对预防性治疗有效。在我们的研究中,我们评估了择期TEVAR与挽救性TEVAR治疗AEF的效果。在我们的单中心回顾性队列研究中,本研究纳入了47例cT4M0期EC患者,并根据TEVAR是否在出血性AEF发生之前进行,将他们分为挽救性组(S组)和择期组(E组)。我们的研究结果包括TEVAR后的生存率和并发症发生率。E组在90天和180天的总体90天生存率和无主动脉事件生存率方面均优于S组。E组中有更多患者能够接受后续的放化疗或食管切除术。E组中与AEF相关的并发症显著减少,包括TEVAR后复发性出血事件、低灌注相关器官损伤和血流感染。对于晚期EC侵犯主动脉的患者,与挽救性TEVAR相比,择期TEVAR可带来早期总体和无主动脉事件生存获益。通过减少与AEF相关的并发症,择期TEVAR可为更多患者提供后续的根治性治疗。